JAMA Clinical Reviews Understanding Lipids and Cardiovascular Risk Through Mendelian Randomization
11 snips
Oct 8, 2019 Explore how mendelian randomization studies reveal insights into cardiovascular risk assessment through low LDL and blood pressure levels with Dr. Brian Ferrance. Discover the impact of genetic variants on cholesterol levels and cardiovascular disease risk, including the role of PCSK9. Learn how maintaining lower LDL and blood pressure levels can reduce cardiovascular risk, and delve into the predictive power of genetic variations for cardiovascular disease.
AI Snips
Chapters
Transcript
Episode notes
Mendelian Randomization Basics
- Mendelian randomization uses genetic variants allocated at conception as natural randomization.
- It allows unconfounded causal inference about biomarkers like LDL cholesterol and disease risk.
PCSK9 Discovery's Impact
- Discovery of PCSK9 mutations linked genetics to LDL cholesterol and cardiovascular risk.
- This early Mendelian randomization shaped the development of PCSK9 inhibitors as a therapy.
LDL Reduction Method Equivalence
- LDL lowering via PCSK9 or statin has identical effects on cardiovascular risk per LDL unit.
- Cardiovascular benefit depends on LDL reduction magnitude, not the lowering method.